1 / 14

Point of Care Testing for Personalised Medicine and Health

This initiative by NHS, patients, academia, industry & charities aims to bridge gaps in translation of diagnostic technology, focusing on clinical validity, utility, cost-effectiveness for personalized medicine. Features innovative biomarker research, clinical informatics, proteomics, and assay development for precision diagnostics. Get involved in cutting-edge diagnostic research for improved healthcare outcomes.

cbacon
Download Presentation

Point of Care Testing for Personalised Medicine and Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diagnostic Evidence Co-operative Leeds Point of Care Testing for Personalised Medicine and Health Michael Messenger A partnership between the NHS, patients, academia, industry and charities

  2. Background to the DECs 1st Gap in Translation 2nd Gap in Translation Capacity and Resource Biomedical Research New IVD Development & Market Approval Clinical Practice & Adoption Translational Continuum (adapted from www.cihr-irsc.gc.ca)

  3. Background to the DECs • Facilitate the generation of evidence on: • clinical validity • clinical utility • cost effectiveness • care pathway benefits …of in vitro diagnostic tests (IVDs) – excludes imaging 1st Gap in Translation DECs Capacity and Resource Biomedical Research New IVD Development & Market Approval Clinical Practice & Adoption Translational Continuum (adapted from www.cihr-irsc.gc.ca) CATALYSE, COLLABORATE, INNOVATE METHODOLOGY

  4. Leeds DEC: Scope & Skills NIHR Biomarkers, BRU & HTC; CRUK / YCR Centre & Programmes Musculoskeletal Colorectal Cancer Urology Liver Core Multi-Disciplinary Diagnostic Research Skills -Health Economics Leeds Institute of Health Sciences -Clinical Informatics MRC Biomedical Informatics Centre -Biobanking Clinical & Biomedical Proteomics Group -Public Involvement Musculoskeletal BRU & LIHS -Assay Development & Validation Clinical & Biomedical Proteomics Group -Clinical Biochemistry LTHT pathology -Study/Trial Design Leeds CTRU -Quality Assurance CTRU & UKNEQAS Delivering Research in Primary and Secondary Care Diagnostics; Prognostics; Monitoring; and Precision Medicine

  5. Personalised Medicine – Opportunity and challenges

  6. Personalised Medicine – Opportunity and challenges

  7. Personalised Medicine and Health Prediction & Prevention Early Diagnosis Prognosis Treatment benefit / response Disease Screening Molecular Phenotyping Monitoring Recovery Death Hospital admission Hospital discharge Chronic disease relapse Disease Free Symptomatic Disease Acute disease diagnosed Asymptomatic Disease Disease response Late side-effects Shift towards maintaining health and preventing disease Treatment initiation

  8. A few issues.. Diagnostic testing strategies are complex interventions requiring multidisciplinary cross-sector expertise. • Poor understanding of end user evidence requirements - focus on test accuracy, not patient outcomes, cost-effectiveness or system benefits. • Inadequate consideration of factors affecting measurement (metrology)- e.g. biological, pre-analytical and analytical variability • Poor study and trial design, inadequate reporting practices and preferential publication of positive results  • Inability to associate cost savings in one area of the healthcare system, due to relatively minor cost outlay elsewhere

  9. When is point of care testing (POCT) needed? • POCT often provides quicker test results, but usually with greater uncertainty (accuracy-1) and cost. • If the time to result is critical, then the benefits may offset any greater diagnostic uncertainty and cost. • Determining which approach to use is often hard without a model.

  10. Technology Accelerator

  11. Case Study Diagnostics for Reduction of Antibiotic Misuse Prof Christoph Wälti & Prof Mark Wilcox

  12. Rapid tests for Infection • Lack of instant and accurate diagnostic tools for infectious diseases leads to inappropriate antimicrobial prescribing • Increased antimicrobial prescribing is associated with increased antimicrobial resistance (AMR) • Collaboration with 3 UK SMEs • Develop and evaluate a rapid point of care test • £3.9 Million from Medical Research Council • Brings together Leeds commercial IP and cross-faculty expertise in:

  13. Wednesday 19th October, Queens Hotel, Leeds https://www.eventbrite.co.uk/e/the-1st-leeds-precision-oncology-symposium-tickets-26373622214

  14. Acknowledgements • All the DEC Leeds collaborators and partners • The Diagnostic Evidence Co-operative Leeds is funded by the National Institute for Health Research and is a partnership between the Leeds Teaching Hospitals Trust and the Universities of Alberta, Edinburgh, Leeds, Oxford, Southampton and University College London. E-mail: NIHRDEC@leeds.ac.uk Web: www.leeds.dec.nihr.ac.uk Twitter: @DEC_Leeds

More Related